Verrica Pharmaceuticals (VRCA) to Release Earnings on Tuesday

Verrica Pharmaceuticals (NASDAQ:VRCA) is expected to post its Q1 2025 quarterly earnings results after the market closes on Tuesday, May 13th. Analysts expect Verrica Pharmaceuticals to post earnings of ($0.10) per share and revenue of $2.53 million for the quarter.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.30 million. On average, analysts expect Verrica Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Trading Up 6.0%

Shares of Verrica Pharmaceuticals stock opened at $0.44 on Monday. The company has a fifty day moving average price of $0.51 and a 200 day moving average price of $0.72. Verrica Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $11.41. The stock has a market cap of $40.68 million, a price-to-earnings ratio of -0.24 and a beta of 1.73.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on VRCA shares. HC Wainwright reaffirmed a “neutral” rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, April 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, April 9th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.50.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its stake in Verrica Pharmaceuticals stock. Bank of America Corp DE grew its stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 347.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 143,818 shares of the company’s stock after purchasing an additional 111,678 shares during the quarter. Bank of America Corp DE owned approximately 0.32% of Verrica Pharmaceuticals worth $101,000 as of its most recent filing with the SEC. 42.45% of the stock is owned by institutional investors and hedge funds.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.